title: Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro.
abstract: The NMDA antagonist and neuroprotective effects of RPR 104632 (2H-1,2,4-benzothiadiazine-1-dioxide-3-carboxylic acid), a new benzothiadiazine derivative, with affinity for the glycine site of the NMDA receptor-channel complex are described. RPR 104632 antagonized the binding of [3H]5,7-dichlorokynurenic acid to the rat cerebral cortex, with a Ki of 4.9 nM. This effect was stereospecific, since the (-)-isomer was 500-fold more potent than the (+)-isomer. The potent affinity of RPR 104632 for the glycine site was confirmed by the observation that RPR 104632 inhibited [3H]N-[1-(2-thienyl)cyclohexyl]-3,4-piperidine ([3H]TCP) binding in the presence of N-methyl-D-aspartate (NMDA) (IC50 = 55 nM), whereas it had no effect on the competitive NMDA site or on the dissociative anaesthetic site. RPR 104632 inhibited the NMDA-evoked increase in guanosine 3',5'-cyclic monophosphate (cGMP) levels of neonatal rat cerebellar slices (IC50 = 890 nM) in a non-competitive manner and markedly reduced NMDA-induced neurotoxicity in rat hippocampal slices and in cortical primary cell cultures. These results suggest that RPR 104632 is a high-affinity specific antagonist of the glycine site coupled to the NMDA receptor channel with potent neuroprotective properties in vitro.
authors: Rhône Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.
authors: A
authors: A
authors: Boireau
authors: C
authors: C
authors: Malgouris
authors: M C
authors: MC
authors: Burgevin
authors: C
authors: C
authors: Pény
authors: G
authors: G
authors: Durand
authors: F
authors: F
authors: Bordier
authors: M
authors: M
authors: Meunier
authors: J M
authors: JM
authors: Miquet
authors: M
authors: M
authors: Daniel
authors: T
authors: T
authors: Chevet
authors: P
authors: P
authors: Jimonet
authors: S
authors: S
authors: Mignani
authors: J C
authors: JC
authors: Blanchard
authors: A
authors: A
authors: Doble
mesh_terms: D000634:Aminoquinolines; D000818:Animals; D001581:Benzothiadiazines / Q000494:pharmacology*; D001667:Binding, Competitive; D002540:Cerebral Cortex / Q000187:drug effects*; D006152:Cyclic GMP / Q000096:biosynthesis; D018691:Excitatory Amino Acid Antagonists / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects* / Q000502:physiology; D066298:In Vitro Techniques; D007736:Kynurenic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D009410:Nerve Degeneration; D010622:Phencyclidine / Q000031:analogs & derivatives* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*
chemical_list: D000634:Aminoquinolines; D001581:Benzothiadiazines; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; C074617:4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline; C103467:RPR 104632; C012058:tenocyclidine; D007736:Kynurenic Acid; D006152:Cyclic GMP; D010622:Phencyclidine; C066192:5,7-dichlorokynurenic acid